The following stories appear in full on today's Vidyya Medical News Service Web site.
David Satcher, MD, PhD, Assistant Secretary for Health and Surgeon General, will release a National Action Agenda for Children's Mental Health, which outlines goals and strategies to improve the services for children and adolescents with mental health problems and their families. According to the report, the nation is facing a public crisis in mental health for children and adolescents.
For more information: Surgeon General To Release A National Action Agenda On Children's Mental Health - 03 January 2001
Taiwan has approved the sale of the abortion pill RU-486, conceding that a ban on the drug had not stopped women from taking it to end unwanted pregnancies. The pill was approved to prevent women from taking the drug on their own, risking excessive bleeding and other dangers, according to Health Administration Director Lee Ming-Liang.
For more information: Abortion Pill Approved In Taiwan
Vidyya has watched the Ugandan Ebola epidemic for several months. Though the disease has spread to three distinct districts, the rate of infection and death has slowed. The cummulative totals for the disease include 426 cases and 172 deaths. Read a short synopsis regarding the current status of the epidemic in today's issue.
For more information: Ebola Update
Antibiotic resistance (AR) is a growing problem that has recently been identified as a major public health threat and priority by several expert committees, including those of the Institute of Medicine, the American Society for Microbiology, as well as by the US Office of Technology Assessment. The continuing emergence of difficult to treat or untreatable nosocomial pathogens such as multidrug resistant Klebsiella, vancomycin resistant enterococci (VRE), and Staphylococcus aureus with intermediate susceptibility to vancomycin and other glycopeptide antibiotics (GISA) threaten the lives of hospitalized individuals and those with chronic conditions and add considerably to health care costs.
For more information: FDA Task Force On Antimicrobial Resistance: Key Recommendations And Report
Malarone (a fixed combination of atovaquone and proguanil hydrochloride) is a new antimalarial drug approved in the United States in July 2000 for both treatment and prophylaxis of malaria. The drug has been shown to be highly efficacious in the treatment of uncomplicated malaria caused by Plasmodium falciparum, including malaria that has been acquired in areas with chloroquine-resistant or multidrug-resistant strains. Malarone is available in adult (250 milligram [mg] atovaquone and 100 mg proguanil hydrochloride per tablet) and pediatric (62.5 mg atovaquone and 25 mg proguanil hydrochloride per tablet) strength forms.
For more information: Information For Health Care Providers - Malarone For Malaria Treatment And Prophylaxis
Today's Vidyya articles are:
As always, we hope you enjoy the issue.